K
Kei Muro
Researcher at National Cancer Research Institute
Publications - 563
Citations - 26712
Kei Muro is an academic researcher from National Cancer Research Institute. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 57, co-authored 478 publications receiving 20277 citations.
Papers
More filters
Journal ArticleDOI
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem,Andrés Cervantes,René Adam,Alberto Sobrero,J.H.J.M. van Krieken,Dan Aderka,E. Aranda Aguilar,Alberto Bardelli,Al B. Benson,György Bodoky,Fortunato Ciardiello,André D'Hoore,Eduardo Díaz-Rubio,J.-Y. Douillard,Michel Ducreux,Alfredo Falcone,Axel Grothey,Thomas Gruenberger,Karin Haustermans,Volker Heinemann,Paulo M. Hoff,C.-H. Köhne,R. Labianca,Pierre Laurent-Puig,Brigette B.Y. Ma,Tim Maughan,Kei Muro,Nicola Normanno,Pia Österlund,Pia Österlund,Wim J.G. Oyen,Demetris Papamichael,George Pentheroudakis,Per Pfeiffer,Timothy J. Price,C.J.A. Punt,Jens Ricke,Arnaud Roth,R. Salazar,Werner Scheithauer,H.-J. Schmoll,Josep Tabernero,Julien Taieb,Sabine Tejpar,Harpreet Wasan,Takayuki Yoshino,Aziz Zaanan,Dirk Arnold +47 more
TL;DR: These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
Journal ArticleDOI
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke,Kei Muro,Eric Van Cutsem,Sang Cheul Oh,György Bodoky,Yasuhiro Shimada,Shuichi Hironaka,Naotoshi Sugimoto,Oleg Lipatov,Tae You Kim,David Cunningham,Philippe Rougier,Yoshito Komatsu,Jaffer A. Ajani,Michael Emig,Roberto Carlesi,David Ferry,Kumari Chandrawansa,Jonathan D. Schwartz,Atsushi Ohtsu +19 more
TL;DR: The combination of ramucirumab with pac litaxel significantly increases overall survival compared with placebo plus paclitaxel, and could be regarded as a new standard second-line treatment for patients with advanced gastric cancer.
Journal ArticleDOI
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer
Toshiaki Watanabe,Michio Itabashi,Yasuhiro Shimada,Shinji Tanaka,Yoshinori Ito,Yoichi Ajioka,Tetsuya Hamaguchi,Ichinosuke Hyodo,Masahiro Igarashi,Hideyuki Ishida,Megumi Ishiguro,Yukihide Kanemitsu,Norihiro Kokudo,Kei Muro,Atsushi Ochiai,Masahiko Oguchi,Yasuo Ohkura,Yutaka Saito,Yoshiharu Sakai,Hideki Ueno,Takayuki Yoshino,Takahiro Fujimori,Nobuo Koinuma,Takayuki Morita,Genichi Nishimura,Yuh Sakata,Keiichi Takahashi,Hiroya Takiuchi,Osamu Tsuruta,Toshiharu Yamaguchi,Masahiro Yoshida,Naohiko Yamaguchi,Kenjiro Kotake,Kenichi Sugihara,Rectum +34 more
TL;DR: The English version of the JSCCR Guidelines 2016 is presented, which can be used as a tool for treating colorectal cancer in actual clinical practice settings and as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient.
Journal ArticleDOI
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang,Narikazu Boku,Taroh Satoh,Min Hee Ryu,Yee Chao,Ken Kato,Hyun Cheol Chung,Jen-Shi Chen,Kei Muro,Won Ki Kang,Kun-Huei Yeh,Takaki Yoshikawa,Sang Cheul Oh,Li Yuan Bai,Takao Tamura,Keun Wook Lee,Yasuo Hamamoto,Jong Gwang Kim,Keisho Chin,Do Youn Oh,Keiko Minashi,Jae Yong Cho,Masahiro Tsuda,Li-Tzong Chen,Li-Tzong Chen +24 more
TL;DR: In this phase 3 study, the survival benefits indicate that nivolumab might be a new treatment option for heavily pretreated patients with advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs,Toshihiko Doi,Raymond Jang,Raymond Jang,Kei Muro,Taroh Satoh,Manuela Machado,Weijing Sun,Weijing Sun,Shadia I. Jalal,Manish A. Shah,Jean Phillipe Metges,Marcelo Garrido,Talia Golan,Talia Golan,Mario Mandalà,Zev A. Wainberg,Daniel V.T. Catenacci,Atsushi Ohtsu,Kohei Shitara,Ravit Geva,Jonathan Bleeker,Andrew H. Ko,Geoffrey Y. Ku,Philip A. Philip,Peter C. Enzinger,Yung-Jue Bang,Diane Levitan,Jiangdian Wang,Minori Koshiji Rosales,Rita P. Dalal,Harry H. Yoon +31 more
TL;DR: Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment.